EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit



Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit



Clinical Chemistry 46(3): 365-372



Background: The acyl glucuronide (AcMPAG) of mycophenolic acid (MPA) has been found to possess pharmacologic and potentially proinflammatory activity in vitro. To establish its pharmacologic and toxicologic relevance in vivo, a reversed-phase HPLC method was modified to simultaneously determine MPA, the phenolic MPA-glucuronide (7-O-MPAG), and AcMPAG. In addition, cross-reactivity of AcMPAG in the Emit assay for MPA was investigated. Methods: The procedure used simple sample preparation, separation with a Zorbax Eclipse-XDB-C8 column, and gradient elution. AcMPAG was quantified as 7-O-MPAG-equivalents. Results: The assay was linear up to 50 mg/L for MPA, 250 mg/L for 7-O-MPAG, and 10 mg/L for AcMPAG (r >0.999). Detection limits were 0.01, 0.03, and 0.04 mg/L for MPA, 7-O-MPAG, and AcMPAG, respectively. The recoveries were 99-103% for MPA, 95-103% for 7-O-MPAG, and 104-107% for AcMPAG. The within-day imprecision was <5.0% for MPA (0.2-25 mg/L), <4.4% for 7-O-MPAG (10-250 mg/L), and ltoreq14% for AcMPAG (0.1-5 mg/L). The between-day imprecision was <6.2%, <4.5%, and ltoreq14% for MPA, 7-O-MPAG, and AcMPAG, respectively. When isolated from microsomes, purified AcMPAG (1-10 mg/L) revealed a concentration-dependent cross-reactivity in an Emit assay for the determination of MPA ranging from 135% to 185%. This is in accordance with the bias between HPLC and Emit calculated in 270 samples from kidney transplant recipients receiving mycophenolate mofetil therapy, which was greater (median, 151.2%) than the respective AcMPAG concentrations determined by HPLC. AcMPAG was found to undergo hydrolysis when samples were stored up to 24 h at room temperature or up to 30 days at 4 degreeC or -20 degreeC. Acidified samples (pH 2.5) were stable up to 30 days at -20 degreeC. Conclusions: The HPLC and Emit methods for AcMPAG described here may allow investigation of its relevance for the immunosuppression and side effects associated with mycophenolate mofetil therapy.

(PDF emailed within 1 workday: $29.90)

Accession: 010443531

Download citation: RISBibTeXText

PMID: 10702523



Related references

A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 883-884: 113-119, 2012

Determination of mycophenolic acid (MPA) and its acyl and phenol glucuronide metabolits simultaneously in human plasma by a simplified HPLC method. Analytical Letters 40(13): 2465-2475, 2007

Determination of the newly detected pharmacologically active acyl glucuronide metabolite of mycophenolic acid by HPLC. Clinical Chemistry 45(6 PART 2): A128, June, 1999

Mathematical Equations to Calculate True Mycophenolic Acid Concentration in Human Plasma by Using Two Immunoassays With Different Cross-Reactivities With Acyl Glucuronide Metabolite Comparison of Calculated Values With Values Obtained by Using an HPLC-UV. Journal of Clinical Laboratory Analysis 27(4): 290-293, 2013

Mathematical equations to calculate true mycophenolic acid concentration in human plasma by using two immunoassays with different cross-reactivities with acyl glucuronide metabolite: comparison of calculated values with values obtained by using an HPLC-UV method. Journal of Clinical Laboratory Analysis 27(4): 290-293, 2014

HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. Journal of Pharmaceutical and Biomedical Analysis 36(3): 649-651, 2004

A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Therapeutic Drug Monitoring 21(3): 322-324, 1999

High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma. Journal Of Chromatography B. 708(1-2): 229-234, Il 24, 1998

Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma. Journal of Pharmaceutical and Biomedical Analysis 50(4): 640-648, 2008

Determination of mycophenolic acid and its phenol glucuronide metabolite in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography B 763(1-2): 35-45, 5 November, 2001

Application of experimental design in optimization of solid phase extraction of mycophenolic acid and mycophenolic acid glucuronide from human urine and plasma and SPE-RP-HPLC method validation. Journal of Pharmaceutical and Biomedical Analysis 47(3): 575-585, 2008

High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma. Therapeutic Drug Monitoring 28(1): 116-122, 2006

Determination of mycophenolic acid and its glucuronide metabolite in plasma. Journal of Pharmaceutical Sciences 61(11): 1750-1753, 1972

The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplantation Proceedings 33(1-2): 1080-1081, 2001

Determination of a prostaglandin D2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detection--a lack of MS/MS selectivity between a glucuronide conjugate and a phase I metabolite. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 837(1-2): 116-124, 2006